A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Tirabrutinib (Primary) ; Entospletinib; Idelalisib
- Indications B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 22 Nov 2017 Planned End Date changed from 1 Aug 2022 to 1 Sep 2022.
- 28 Sep 2017 Planned End Date changed from 1 May 2020 to 1 Aug 2022.
- 28 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History